Drugs of anaesthesia and cancer

Surgical Oncology

Volumn 19, Issue 2, 2010, Pages 63-81

  Santamaria, Letterio B ^a   Schifilliti, Daniela ^a   La Torre, Domenico ^a   Fodale, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Anesthesia; Anesthetics; Cancer; Complications; Effects; General anesthetics; Intravenous anesthetics; Neuromuscular blocking drugs; Nitrous oxide; Oncology; Opioids; Regional anesthesia; Risk; Volatile anesthetics

Indexed keywords

ALFENTANIL; ATRACURIUM; DESFLURANE; DOCOSAHEXAENOIC ACID; ETOMIDATE; FENTANYL; HALOTHANE; HYDROMORPHONE; ICOSAPENTAENOIC ACID; INHALATION ANESTHETIC AGENT; ISOFLURANE; KETAMINE; LIDOCAINE; METHOTREXATE; MORPHINE; NADOLOL; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; OPIATE; OXYCODONE; PROCAINE; PROPOFOL; REMIFENTANIL; ROPIVACAINE; SEVOFLURANE; SUFENTANIL; THIOPENTAL; TRAMADOL; UNINDEXED DRUG; XYLAZINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER PAIN; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLECYSTECTOMY; CLINICAL TRIAL; CYTOTOXICITY; DNA FRAGMENTATION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG SAFETY; GENE OVEREXPRESSION; GENERAL ANESTHESIA; HUMAN; IC 50; LIVER CELL DAMAGE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NERVE BLOCK; NONHUMAN; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REGIONAL ANESTHESIA; REVIEW; SINGLE DRUG DOSE; SPINAL ANESTHESIA; STOMACH MUCOSA LESION; UNSPECIFIED SIDE EFFECT;

ANALGESICS, OPIOID; ANESTHESIA, CONDUCTION; ANESTHESIA, GENERAL; ANESTHESIA, INTRAVENOUS; ANESTHETICS; ANESTHETICS, INHALATION; HUMANS; NEOPLASMS; NEUROMUSCULAR BLOCKING AGENTS; NITROUS OXIDE; PROGNOSIS; RISK;

EID: 77952580978     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2009.03.007     Document Type: Review

References (136)

1. Kvolik S., Glavas-Obrovac L., Bares V., and Karner I. Effects of inhalation anaesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci 77 (2005) 2369-2383
2. Mammoto T., Mukai M., Mammoto A., Yamanaka Y., Hayashi Y., Mashimo T., et al. Intravenous anaesthetic, propofol inhibits invasion of cancer cells. Cancer Lett 184 (2002) 165-170
3. Tatsuya I., Tsunehisa N., Kazuhiko F., Gregg L.S., and Kiichi H. Reversible inhibition of hypoxia-inducible factor 1 activation by exposure of hypoxic cells to the volatile anesthetic halothane. FEBS Lett 509 (2001) 225-229
4. Melamed R., Bar-Yosef S., Shakhar G., Shakhar K., and Ben-Eliyahu S. Suppression of natuarl killer cell activity and promotion of tumour metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg 97 (2003) 1331-1339
5. Van de Louw A., Plaud B., and Debaene B. Use of sevoflurane for surgery of phaeochromocytoma. Ann Fr Anesth Reanim 17 (1998) 301-305
6. ASA ad hoc Committee on Effects of Trace Anaesthetics on the Operating Room Personnel. Occupational disease among operating room personnel: a national study. Anesthesiology 41 (1974) 321-340
7. Mazze R.I., Fujinaga M., Rice S.A., Harris S.B., and Baden J.M. Reproductive and teratogenic effects of nitrous oxide, halothane, isoflurane, and enflurane in Sprague-Dawley rats. Anesthesiology 64 (1986) 339-344
8. Eger II E.I., White A.E., Brown C.L., Biava C.G., Corbett T.H., and Stevens W.C. A test of the carcinogenicity of enflurane, isoflurane, halothane, methoxyflurane and nitrous oxide in mice. Anaesth Analg 57 (1978) 678-694
9. Brasil L.J., San-Miguel B., Kretzmann N.A., Gomes Do Amaral J.L., Zettler C.G., Marroni N., et al. Halothane induces oxidative stress and NF-kB activation in rat liver: protective effect of propofol. Toxicology 227 (2007) 53-61
10. Katzav S., Shapiro J., Segal S., and Feldman M. General anesthesia during excision of a mouse tumor accelerates postsurgical growth of metastases by suppression of natural killer cell activity. Isr J Med Sci 22 (1986) 339-345
11. Waxler B., Zhang X., and Wezeman F.H. Anesthetic agents modify tissue proteinase inhibitor content and tumor behaviour. J Lab Clin Med 123 (1994) 53-58
12. Page G.G., and Ben-Eliyahu S. Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus/estrus in rats. Breast Cancer Res Treat 45 (1997) 159-167
13. Bar-Yosef S., Melamed R., Page G.G., Shakhar G., Shakhar K., and Ben-Eliyahu S. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 94 (2001) 1066-1073
14. Valtcheva R., Stephanova E., Jordanova A., Pankov R., Altankov G., and Lalchev Z. Effect of halothane on lung carcinoma cells A 549. Chem Biol Interact 146 (2003) 191-200
15. Tas P.W., and Roewer N. The volatile anesthetic enflurane activates capacitative Ca2+ channels in rat glioma C6 cells. Toxicol Lett 100-101 (1998) 265-269
16. Singh G., Janicki P.K., Horn J.L., Janson V.E., and Franks J.J. Inhibition of plasma membrane Ca(2+)-ATPase pump activity in cultured C6 glioma cells by halothane and xenon. Life Sci 56 (1995) 219-224
17. Atcheson R., Bjornstrom K., Hirst R.A., Rowbotham D.J., and Lambert D.G. Effect of halothane on K+ and carbachol stimulated [3H]noradrenaline release and increased [Ca2+] in SH-SY5Y human neuroblastoma cells. Br J Anaesth 79 (1997) 78-83
18. Smart D., Smith G., and Lambert D.G. Halothane and isoflurane enhance basal and carbachol-stimulated inositol(1,4,5)triphosphate formation in SH-SY5Y human neuroblastoma cells. Biochem Pharmacol 47 (1994) 939-945
19. Mitsuhata H., Shimizu R., and Yokoyama M.M. Suppressive effects of volatile anaesthetics on cytokine release in human peripheral blood mononuclear cells. Int J Immunopharmacol 17 (1995) 529-534
20. Xie Z., Dong Y., Maeda U., Moir R.D., Xia W., Culley D.J., et al. The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci 27 (2007) 1247-1254
21. Xie Z., Dong Y., Maeda U., Alfille P., Culley D.J., Crosby G., et al. The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology 104 (2006) 988-994
22. Wei H., Kang B., Wei W., Liang G., Meng Q.C., Li Y., et al. Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently. Brain Res 1037 (2005) 139-147
23. Kuroda M., Yoshikawa D., Nishikawa K., Saito S., and Goto F. Volatile anesthetics inhibit calcitonin gene-related peptide receptor-mediated responses in pithed rats and human neuroblastoma cells. J Pharmacol Exp Ther 311 (2004) 1016-1022
24. Huang Y., and Zuo Z. Isoflurane enhances the expression and activity of glutamate transporter type 3 in C6 glioma cells. Anesthesiology 99 (2003) 1346-1353
25. De Rossi L.W., Brueckmann M., Rex S., Barderschneider M., Buhre W., and Rossaint R. Xenon and isoflurane differentially modulate lipopolysaccharide-induced activation of the nuclear transcription factor KB and production of tumor necrosis factor-α and interleukin-6 in monocytes. Anesth Analg 98 (2004) 1007-1012
26. Ke J.J., Zhan J., Feng X.B., Wu Y., Rao Y., and Wang Y.L. A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care 36 (2008) 74-78
27. Wada H., Seki S., Takahashi T., Kawarabayashi N., Higuchi H., Habu Y., et al. Combined spinal and general anaesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology 106 (2007) 499-506
28. Bedforth N.M., Girling K.J., Skinner H.J., and Mahajan R.P. Effects of desflurane on cerebral autoregulation. Br J Anaesth 87 (2001) 193-197
29. Boisson-Bertrand D., Laxenaire M.C., and Mertes P.M. Recovery after prolonged anaesthesia for acoustic neuroma surgery: desflurane versus isoflurane. Anaesth Intensive Care 34 (2006) 338-342
30. Kushida A., Inada T., and Shingu K. Enhancement of antitumor immunity after propofol treatment in mice. Immunopharmacol Immunotoxicol 29 (2007) 477-486
31. Siddiqui R.A., Zerouga M., Wu M., Castillo A., Harvey K., Zaloga G.P., et al. Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res 7 (2005) 645-654
32. Garib V., Lang K., Niggemann B., Zänker K.S., Brandt L., and Dittmar T. Propofol-induced calcium signalling and actin reorganization within breast carcinoma cells. Eur J Anaesthesiol 22 (2005) 609-615
33. Garib V., Niggemann B., Zänker K.S., Brandt L., and Kubens B.S. Influence of non-volatile anesthetics on the migration behavior of the human breast cancer cell line MDA-MB-468. Acta Anaesthesiol Scand 46 (2002) 836-844
34. Saito Shibakawa Y., Sasaki Y., Goshima Y., Echigo N., Kamiya Y., Kurahashi K., et al. Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide. Br J Anaesth 95 (2005) 803-810
35. Sikand K.S., Hirota K., Smith G., and Lambert D.G. Etomidate inhibits [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells. Neurosci Lett 236 (1997) 87-90
36. Absalom A., Pledger D., and Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 54 (1999) 861-867
37. Wagner R.L., White P.F., Kan P.B., Rosenthal M.H., and Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 310 (1984) 1415-1421
38. Bentley M.W., Stas J.M., Johnson J.M., Viet B.C., and Garrett N. Effects of preincisional ketamine treatment on natural killer cell activity and postoperative pain management after oral maxillofacial surgery. AANA J 73 (2005) 427-436
39. Chang Y., Chen T.L., Sheu J.R., and Chen R.M. Suppressive effects of ketamine on macrophage functions. Toxicol Appl Pharmacol 204 (2005) 27-35
40. Takenaka I., Ogata M., Koga K., Matsumoto T., and Shigematsu A. Ketamine suppresses endotoxin-induced tumor necrosis factor alpha production in mice. Anesthesiology 80 (1994) 402-408
41. Kawasaki T., Ogata M., Kawasaki C., Ogata J., Inoue Y., and Shigematsu A. Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro. Anesth Analg 89 (1999) 665-669
42. Wang E., Guo Q.L., Hu S., and Wang Y.J. Effects of intravenous anesthetics on LPS-induced production of tumour necrosis factor-alpha from primary cultures of rat glial cells in vitro. Zhong Nan Da Xue Xue Bao Yi Xue Ban 32 (2007) 413-416
43. Danielian A.A., Mirakian M.M., and Aǐrapetian S.N. The dehydration action of ketamine on tumorous and normal glandular breast tissues in vitro. Eksp Klin Farmakol 62 (1999) 51-54
44. Danielian A.A., Mirakian M.M., and Aǐrapetian S.N. The dehydrating action of ketamine on malignant breast tumors. Vopr Onkol 44 (1998) 395-397
45. Lee K.H., Ko B.H., Paik J.Y., Jung K.H., Choe Y.S., Choi Y., et al. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med 46 (2005) 1531-1536
46. Choi S.J., Kim M.H., Lim S.W., and Gwak M.S. Effect of ketamine on apoptosis by energy deprivation in astroglioma cells using flow cytometry system. J Korean Med Sci 20 (2005) 113-120
47. Lundy J., Lovett III E.J., and Conran P. Pulmonary metastases, a potential biologic consequence of anesthetic-induced immunosuppression by thiopental. Surgery 82 (1977) 254-256
48. Lovett III E.J., Varani J., and Lundy J. Suppressor cells and increased primary tumor growth rate induced by thiopental. J Surg Oncol 22 (1983) 26-32
49. Lovett III E.J., Alderman J., Munster E., and Lundy J. Suppressive effects of thiopental and halothane on specific arms of the immune response. J Surg Oncol 15 (1980) 327-334
50. Duncan P.G., Cullen B.F., and Ray-Keil L. Thiopental inhibition of tumor immunity. Anesthesiology 46 (1977) 97-101
51. Ben-Eliyahu S., Shakhar G., Rosenne E., Levinson Y., and Beilin B. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology 91 (1999) 732-740
52. chiyama T., Nishikawa M., Lipton J.M., Matsubara T., Takashi H., and Furukawa S. Thiopental inhibits NF-kappaB activation in human glioma cells and experimental brain inflammation. Brain Res 911 (2001) 56-61
53. Loop T., Humar M., Pischke S., Hoetzel A., SchmidtR P.H.L., et al. Thiopental inhibits tumor necrosis factor α-induced activation of nuclear factor kB through suppression of IkB kinase activity. Anesthesiology 99 (2003) 360-367
54. Lambert D.G., Willets J.M., Atcheson R., Frost C., Smart D., Rowbotham D.J., et al. Effects of propofol and thiopentone on potassium- and carbachol-evoked [3H]noradrenaline release and increased [Ca2+]i from SH-SY5Y human neuroblastoma cells. Biochem Pharmacol 51 (1996) 1613-1621
55. Coate W.B., Ulland B.M., and Lewis T.R. Chronic exposure to low concentrations of halothane-nitrous oxide: lack of carcinogenic effect in the rat. Anesthesiology 50 (1979) 306-309
56. Kano Y., Sakamoto S., Sakuraya K., Kubota T., Hida K., Suda K., et al. Effect of nitrous oxide on human bone marrow cells and its synergistic effect with methionine and methotrexate on functional folate deficiency. Cancer Res 41 (1981) 4698-4701
57. Kroes A.C., Ermens A.A., Lindemans J., and Abels J. Effects of 5-fluorouracil treatment of rat leukemia with concomitant inactivation of cobalamin. Anticancer Res 6 (1986) 737-742
58. Kroes A.C., Lindemans J., and Abels J. Synergistic growth inhibiting effect of nitrous oxide and cycloleucine in experimental rat leukaemia. Br J Cancer 50 (1984) 793-800
59. Kroes A.C., Lindemans J., Hagenbeek A., and Abels J. Nitrous oxide reduces growth of experimental rat leukemia. Leuk Res 8 (1984) 441-448
60. Griffith C.D., and Kamath M.B. Effect of halothane and nitrous oxide anaesthesia on natural killer lymphocytes from patients with benign and malignant breast disease. Br J Anaesth 58 (1986) 540-543
61. Ermens A.A., Schoester M., Spijkers L.J., Lindemans J., and Abels J. Toxicity of methotrexate in rats preexposed to nitrous oxide. Cancer Res 49 (1989) 6337-6341
62. Abels J., Kroes A.C., Ermens A.A., van Kapel J., Schoester M., Spijkers L.J., et al. Anti-leukemic potential of methyl-cobalamin inactivation by nitrous oxide. Am J Hematol 34 2 (1990) 128-131
63. Ermens A.A., Vink N., Schoester M., van Lom K., Lindemans J., and Abels J. Nitrous oxide selectively reduces the proliferation of the malignant cells in experimental rat leukaemia. Cancer Lett 45 (1989) 123-128
64. Crespo M.L., Giménez A., Bas T., García C., Puertes I.R., and Viña J.R. Effect of nitrous oxide and propofol on amino acid metabolism in neoplasic patients. Nutr Cancer 27 (1997) 80-83
65. Hopkins M.P., von Gruenigen V., Haller N.A., and Holda S. The effect of various insufflation gases on tumor implantation in an animal model. Am J Obstet Gynecol 187 (2002) 994-996
66. Neuhaus S.J., Ellis T., Rofe A.M., Pike G.K., Jamieson G.G., and Watson D.I. Tumor implantation following laparoscopy using different insufflation gases. Surg Endosc 12 (1998) 1300-1302
67. Neuhaus S.J., Watson D.I., Ellis T., Rowland R., Rofe A.M., Pike G.K., et al. Wound metastasis after laparoscopy with different insufflation gases. Surgery 123 (1998) 579-583
68. Resendes M.C., Kalogeros G.C., Dixon S.J., and Philp R.B. Nitrous oxide enhances Na+/Ca++ exchange in the neuroblastoma cell line SK-N-SH. J Pharmacol Exp Ther 280 (1997) 795-801
69. Weber N.C., Kandler J., Schlack W., Grueber Y., Frädorf J., and Preckel B. Intermitted pharmacologic pretreatment by xenon, isoflurane, nitrous oxide, and the opioid morphine prevents tumor necrosis factor alpha-induced adhesion molecule expression in human umbilical vein endothelial cells. Anesthesiology 108 (2008) 199-207
70. Page G.G., Blakely W.P., and Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 90 (2001) 191-199
71. Sacerdote P. Opioids and the immune system. Palliat Med 20 (2006) 9-15
72. El Mouedden M., and Meert T.F. The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain. Pharmacol Biochem Behav 87 (2007) 30-40
73. El Mouedden M., and Meert T.F. Pharmacological evaluation of opioid and non-opioid analgesics in a murine bone cancer model of pain. Pharmacol Biochem Behav 86 (2007) 458-467
74. Shavit Y., Ben-Eliyahu S., Zeidel A., and Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 11 (2004) 255-260
75. Li W., Tang H.Z., Jiang Y.B., and Xu M.X. Influence of different doses of fentanyl on T-lymphocyte subpopulations and natural killer cells of patients with esophageal tumor during preoperation and postoperation. Ai Zheng 22 (2003) 634-636
76. Beilin B., Shavit Y., Hart J., Mordashov B., Cohn S., Notti I., et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 82 (1996) 492-497
77. Beilin B., Shavit Y., Cohn S., and Kedar E. Narcotic-induced suppression of natural killer cell activity in ventilated and nonventilated rats. Clin Immunol Immunopathol 64 (1992) 173-176
78. Franchi S., Panerai A.E., and Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 21 (2007) 767-774
79. Atcheson R., Rowbotham D.J., and Lambert D.G. Fentanyl inhibits the release of [3H]noradrenaline from SH-SY5Y human neuroblastoma cells. Br J Anaesth 72 (1994) 98-103
80. Coles J.P., Leary T.S., Monteiro J.N., Brazier P., Summors A., Doyle P., et al. Propofol anesthesia for craniotomy: a doubleblind comparison of remifentanil, alfentanil, and fentanyl. J Neurosurg Anesthesiol 12 (2000) 15-20
81. Tipps L.B., Coplin W.M., Murry K.R., and Rhoney D.H. Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care unit. Neurosurgery 46 (2000) 596-601
82. Lobo F., and Beiras A. Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. J Neurosurg Anesthesiol 19 (2007) 183-189
83. Djian M.C., Blanchet B., Pesce F., Sermet A., Disdet M., Vazquez V., et al. Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trial. Clin Ther 28 (2006) 560-568
84. Fodale V., Schifilliti D., Conti A., Lucanto T., Pino G., and Santamaria L.B. Transcranial Doppler and anesthetics. Acta Anaesthesiol Scand 52 (2008) 319-326
85. Valién J.L., Hernando A.N., Gascón A.H., Francés R.C., and Lobera J.C. Cellular immune response to 3 anesthetic techniques for simple abdominal hysterectomy. Rev Esp Anestesiol Reanim 54 (2007) 523-528
86. Jaeger K., Scheinichen D., Heine J., André M., Bund M., Piepenbrock S., et al. Remifentanil, fentanyl, and alfentanil have no influence on the respiratory burst of human neutrophils in vitro. Acta Anaesthesiol Scand 42 (1998) 1110-1113
87. De Leon-Casasola O.A., and Lema M.J. Epidural bupivacaine/sufentanil therapy for postoperative pain control in patients tolerant to opioid and unresponsive to epidural bupivacaine/morphine. Anesthesiology 80 (1994) 303-309
88. Soltész S., Biedler A., Silomon M., Schöpflin I., and Molter G.P. Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. Br J Anaesth 86 (2001) 763-768
89. Weinstabl C., Mayer N., Richling B., Czech T., and Spiss C.K. Effect of sufentanil on intracranial pressure in neurosurgical patients. Anaesthesia 46 (1991) 837-840
90. Manfredi P.L., Chandler S.W., Patt R., and Payne R. High-dose epidural infusion of opioids for cancer pain: cost issues. J Pain Symptom Manage 13 (1997) 118-121
91. El Azab S.R., Rosseel P.M., De Lange J.J., van Wijk E.M., van Strik R., and Scheffer G.J. Effect of VIMA with sevoflurane versus TIVA with propofol or midazolam-sufentanil on the cytokine response during CABG surgery. Eur J Anaesthesiol 19 (2002) 276-282
92. Helmy S.A., Wahby M.A., and El-Nawaway M. The effect of anaesthesia and surgery on plasma cytokine production. Anaesthesia 54 (1999) 733-738
93. Wiffen P.J., and McQuay H.J. Oral morphine for cancer pain. Cochrane Database Syst Rev 4 (2007) CD003868
94. Miura H., Taira O., Hiraguri S., and Kato H. Morphine for the management of pain in lung cancer. Nippon Rinsho 60 (2002) 676-680
95. Donnelly S., Davis M.P., Walsh D., Naughton M., and World Health Organization. Morphine in cancer pain management: a practical guide. Support Care Cancer 10 (2002) 13-35
96. Kato Y., and Kato A. Role of continuous intravenous infusion of morphine in the cancer pain relieving therapy. Nippon Rinsho 59 (2001) 1789-1793
97. Gilmer-Hill H.S., Boggan J.E., Smith K.A., and Wagner Jr. F.C. Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Surg Neurol 51 (1999) 12-15
98. Simon R.H., and Arbo T.E. Morphine increases metastatic tumor growth. Brain Res Bull 16 (1986) 363-367
99. Yeager M.P., and Colacchio T.A. Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg 126 (1991) 454-456
100. Kuraishi Y. Effects of morphine on cancer pain and tumor growth and metastasis. Nippon Rinsho 59 (2001) 1669-1674
101. Sasamura T., Nakamura S., Iida Y., Fujii H., Murata J., Saiki I., et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol 441 (2002) 185-191
102. Sacerdote P., Bianchi M., Gaspani L., Manfredi B., Maucione A., Terno G., et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 90 (2000) 1411-1414
103. Harimaya Y., Koizumi K., Andoh T., Nojima H., Kuraishi Y., and Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett 187 (2002) 121-127
104. Tegeder I., Grösch S., Schmidtko A., Häussler A., Schmidt H., Niederberger E., et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 63 (2003) 1846-1852
105. Hatsukari I., Hitosugi N., Ohno R., Hashimoto K., Nakamura S., Satoh K., et al. Induction of apoptosis by morphine in human tumor cell lines in vitro. Anticancer Res 27 (2007) 857-864
106. Hatsukari I., Hitosugi N., Matsumoto I., Nagasaka H., and Sakagami H. Induction of early apoptosis marker by morphine in human lung and breast carcinoma cell lines. Anticancer Res 23 (2003) 2413-2417
107. Cheng W.F., Chen L.K., Chen C.A., Chang M.C., Hsiao P.N., Su Y.N., et al. Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. Mol Ther 13 (2006) 203-210
108. King T., Vardanyan A., Majuta L., Melemedjian O., Nagle R., Cress A.E., et al. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain 132 (2007) 154-168
109. Hashiguchi S., Morisaki H., Kotake Y., and Takeda J. Effects of morphine and its metabolites on immune function in advanced cancer patients. J Clin Anesth 17 (2005) 575-580
110. Chrubasik S., Chrubasik J., and Friedrich G. Clinical use of alfentanil. Anaesthesiol Reanim 19 (1994) 60-66
111. Cairns R. The use of oxycodone in cancer-related pain: a literature review. Int J Palliat Nurs 7 (2001) 522-527
112. Biancofiore G. Oxycodone controlled release in cancer pain management. Ther Clin Risk Manage 2 (2006) 229-234
113. Kumar M.G., and Lin S. Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms. J Pharm Pharm Sci 10 (2007) 504-518
114. Sacerdote P., Bianchi M., Manfredi B., and Panerai A.E. Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain 72 (1997) 325-330
115. Gaspani L., Bianchi M., Limiroli E., Panerai A.E., and Sacerdote P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol 129 (2002) 18-24
116. Amann A., Rieder J., Fleischer M., Niedermüller P., Hoffmann G., Amberger A., et al. The influence of atracurium, cisatracurium, and mivacurium on the proliferation of two human cell lines in vitro. Anesth Analg 93 (2001) 690-696
117. Magorian T., Wood P., Caldwell J., Fisher D., Segredo V., Szenohradszky J., et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 80 (1995) 754-759
118. Sessler D.I. Does regional analgesia reduce the risk of cancer recurrence? A hypothesis. Eur J Cancer Prev 17 (2008) 269-272
119. Sessler D.I. Regional anaesthesia and cancer recurrence risk. Rev Esp Anestesiol Reanim 55 (2008) 133-134
120. Arain M.R., and Buggy D.J. Anaesthesia for cancer patients. Curr Opin Anaesthesiol 20 (2007) 247-253
121. Groetelaers R.P., van Berlo C.L., Nijhuis P.H., Schapers R.F., and Gerritsen H.A. Axillary recurrences after negative sentinel lymph node biopsy under local anaesthesia for breast cancer: a follow-up study after 5 years. Eur J Surg Oncol (2008) [Epub ahead of print]
122. Kumar C.M., Corbett W.A., and Wilson R.G. Spinal anaesthesia with a micro-catheter in high-risk patients undergoing colorectal cancer and other major abdominal surgery. Surg Oncol 17 (2008) 73-79
123. Greengrass R., O'Brien F., Lyerly K., Hardman D., Gleason D., D'Ercole F., et al. Paravertebral block for breast cancer surgery. Can J Anaesth 43 (1996) 858-861
124. Hashimoto T., Hashimoto S., Hori Y., Nakagawa H., and Hosokawa T. Epidural anaesthesia blocks changes in peripheral lymphocytes subpopulation during gastrectomy for stomach cancer. Acta Anaesthesiol Scand 39 (1995) 294-298
125. Sharma S., Rajagopal M.R., Palat G., Singh C., Haji A.G., and Jain D. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage (2008) [Epub ahead of print]
126. Massey G.V., Pedigo S., Dunn N.L., Grossman N.J., and Russell E.C. Continuous lidocaine infusion for the relief of refractory malignant pain in a terminally ill pediatric cancer patient. J Pediatr Hematol Oncol 24 7 (2002) 566-568
127. Sakaguchi M., Kuroda Y., and Hirose M. The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth Analg 102 (2006) 1103-1107
128. Mammoto T., Higashiyama S., Mukai M., Mammoto A., Ayaki M., Mashimo T., et al. Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF). J Cell Physiol 192 (2002) 351-358
129. Martinsson T., and Fowler C.J. Local anaesthetics do not affect protein kinase C function in intact neuroblastoma cells. Life Sci 53 (1993) 1557-1565
130. Di Padova M., Barbieri R., Fanciulli M., Arcuri E., and Floridi A. Effect of local anesthetic ropivacaine on the energy metabolism of Ehrlich ascites tumor cells. Oncol Res 10 (1998) 491-498
131. Feinstein D.L., Murphy P., Sharp A., Galea E., Gavrilyuk V., and Weinberg G. Local anesthetics potentiate nitric oxide synthase type 2 expression in rat glial cells. J Neurosurg Anesthesiol 13 (2001) 99-105
132. Villar-Garea A., Fraga M.F., Espada J., and Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 63 (2003) 4984-4989
133. Mariggiò M.A., Cafaggi S., Ottone M., Parodi B., Vannozzi M.O., Mandys V., et al. Inhibition of cell growth, induction of apoptosis and mechanism of action of the novel platinum compound cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N(4)]-chloride platinum (II) monohydrochloride monohydrate. Invest New Drugs 22 (2004) 3-16
134. Viale M., Pastrone I., Pellecchia C., Vannozzi M.O., Cafaggi S., and Esposito M. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. Anticancer Drugs 9 5 (1998) 457-463
135. Angileri F.F., Aguennouz M., Conti A., La Torre D., Cardali S., Crupi R., et al. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer 112 10 (2008) 2258-2266
136. Sessler D.I., Ben-Eliyahu S., Mascha E.J., Parat M.O., and Buggy D.J. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contemp Clin Trials 29 (2008) 517-526